Faculty Collaboration Database

Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987 Jul;5(7):1026-32

Date

07/01/1987

Pubmed ID

3474356

DOI

10.1200/JCO.1987.5.7.1026

Scopus ID

2-s2.0-0023595294 (requires institutional sign-in at Scopus site)   91 Citations

Abstract

The prognostic significance of initial clinical and laboratory parameters was evaluated in 125 children with acute myelogenous leukemia (AML) treated on two consecutive protocols (VAPA and 80-035). Both protocols used an anthracycline with cytosine arabinoside (ara-C) for induction therapy followed by 12 to 14 months of intensive sequential postremission chemotherapy. Results are similar for the two treatment regimens. Seventy-two percent of patients achieved a complete remission, with 42% projected 5-year disease-free survival for the complete responders. Monocytic or myelomonocytic leukemic subtype (French-American-British [FAB] types M4 and M5), WBC count less than 100,000/microL, and age less than 2 years at diagnosis all predicted increased risk of relapse and decreased overall survival in univariate analyses. FAB subtype and high white count continued to predict for an increased risk of relapse in multivariate analyses and only M5 leukemic subtype independently predicted for poor survival. Patients with M4 or M5 leukemic subtype had a higher incidence of initial relapses in the CNS. The addition of intrathecal cytosine arabinoside in the second protocol, 80-035, decreased the percentage of patients with initial failure in the CNS, but did not improve overall survival. Improved CNS prophylaxis, better systemic therapy, and/or different treatment strategies are needed to improve therapy in these high-risk patients.

Author List

Grier HE, Gelber RD, Camitta BM, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ

MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Child
Cytarabine
Daunorubicin
Doxorubicin
Humans
Leukemia, Myeloid, Acute
Leukocyte Count
Prednisolone
Remission Induction
Risk
Time Factors
Vincristine